RAP media thread., page-985

Yes indeed, the time has come!! As per the latest Coviu announcement below ...

"ResApp and Coviu have signed a binding commercial terms sheet and have agreed upon a per test fee for the use of ResAppDx-EU on Coviu’s telehealth platform. The per test fee received by ResApp is within the previously targeted range of $5-10 per test. The non-exclusive licence will
have an initial term of two years and may be extended by mutual agreement. Either party may terminate the licence by providing 60 days written notice. Coviu and ResApp intend to rapidly progress to a formal licence agreement and plan to have ResAppDx-EU available for use by all clinicians on Coviu’s platform within a few months"

Cheers

Red bar